Results 221 to 230 of about 26,368 (251)

nab-Paclitaxel plus Gemcitabin

best practice onkologie, 2012
openaire   +1 more source

nab-Paclitaxel auch langfristig erfolgreich

Info Onkologie, 2015
openaire   +1 more source

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

The Lancet Gastroenterology and Hepatology, 2020
Philip A Philip, Jill Lacy, Asfar S Azmi
exaly  

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

New England Journal of Medicine, 2013
E Gabriela Chiorean, Wen Wee, Reni Michele   +2 more
exaly  

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncology, The, 2020
Hiroji Iwata, Véronique Diéras, Eric P Winer   +2 more
exaly  

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

New England Journal of Medicine, 2018
Hope S Rugo, Hiroji Iwata, Véronique Diéras   +2 more
exaly  

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

Lancet Oncology, The, 2016
Michael Untch, Christian Jackisch, Andreas Schneeweiß   +2 more
exaly  

Nab-paclitaxel

Reactions Weekly
openaire   +1 more source

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

New England Journal of Medicine, 2019
Sercan Aksoy
exaly  

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

The Lancet Gastroenterology and Hepatology, 2017
Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani   +2 more
exaly